Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

被引：0
|
作者：
Daniele Ouellet
Nastya Kassir
Joannellyn Chiu
Mohamad-Samer Mouksassi
Cathrine Leonowens
Donna Cox
Douglas J. DeMarini
Olivia Gardner
Wendy Crist
Kiran Patel
机构：
[1] GlaxoSmithKline,
[2] Janssen Research & Development,undefined
[3] Certara Strategic Consulting,undefined
[4] Inncelerex,undefined
[5] ,undefined
[6] Genentech,undefined
[7] Incyte Corporation,undefined
[8] Teva Pharmaceuticals,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 77卷
关键词：
Pharmacokinetics; NONMEM; Exposure–response; Melanoma; MEK inhibitor;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：807 / 817
页数：10
相关论文
共 50 条
  • [1] Population pharmacokinetics and exposure-response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma
    Ouellet, Daniele
    Kassir, Nastya
    Chiu, Joannellyn
    Mouksassi, Mohamad-Samer
    Leonowens, Cathrine
    Cox, Donna
    DeMarini, Douglas J.
    Gardner, Olivia
    Crist, Wendy
    Patel, Kiran
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (04) : 807 - 817
  • [2] Exposure-Response Analysis of the Effect of Trametinib, a MEK inhibitor, on Tumor Size in Patients with V600 BRAF Mutation Positive Melanoma
    Chiu, Joannellyn
    Ouellet, Daniele
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S115 - S115
  • [3] Concomitant Oral and Intravenous Pharmacokinetics of Dabrafenib, a BRAF Inhibitor, in Patients With BRAF V600 Mutation-Positive Solid Tumors
    Denton, Cathrine L.
    Minthorn, Elisabeth
    Carson, Stanley W.
    Young, Graeme C.
    Richards-Peterson, Lauren E.
    Botbyl, Jeffrey
    Han, Chao
    Morrison, Royce A.
    Blackman, Samuel C.
    Ouellet, Daniele
    JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (09): : 955 - 961
  • [4] POPULATION PHARMACOKINETICS OF DABRAFENIB (GSK2118436), A BRAF INHIBITOR IN DEVELOPMENT FOR THE TREATMENT OF BRAF V600 MUTATION POSITIVE MELANOMA
    Gibiansky, E.
    O'Hagan, A.
    Haney, P.
    Switzky, J. C.
    Goodman, V. L.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S83 - S83
  • [5] Dabrafenib, Alone or in Combination with Trametinib, in Pediatric Patients with BRAF V600 Mutation-Positive Langerhans Cell Histiocytosis
    Whitlock, James A.
    Geoerger, Birgit
    Roughton, Michael
    Choi, Jeea
    Osterloh, Lisa
    Russo, Mark
    Hargrave, Darren
    BLOOD, 2021, 138
  • [6] EXPOSURE-RESPONSE MODELING OF THE EFFECT OF DABRAFENIB, A BRAF INHIBITOR, ON OBJECTIVE RESPONSE RATE (ORE) IN PATIENTS WITH BRAF V600 MUTATION POSITIVE MELANOMA.
    Nebot, N.
    Ma, B.
    Haney, P.
    O'Hagan, A.
    Swann, R. S.
    Goodman, V. L.
    Ouellet, D.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2013, 93 : S65 - S66
  • [7] Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF V600 Mutation
    Dhillon, Sohita
    TARGETED ONCOLOGY, 2016, 11 (03) : 417 - 428
  • [8] Implementation of a National Plan in Argentina to Detect Braf V600 Mutation-Positive Metastatic Melanoma
    Latorre, M. C.
    Gutierrez, M.
    Garcia-Rivello, H. J.
    Livellaro, B.
    Lozano, G. C.
    Maldonado, C.
    Volonteri, V. I.
    De La Iglesia, P.
    Aylagas, D.
    Garritano, G.
    Carrizo, M.
    Mocetti, E. M.
    Moffa, F.
    MODERN PATHOLOGY, 2014, 27 : 136A - 136A
  • [9] NICE guidance on dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
    Tucker, Helen
    Umeweni, Nwamaka
    Robertson, Janet
    Adam, Jane
    LANCET ONCOLOGY, 2014, 15 (13): : 1425 - 1426
  • [10] Real-world efficacy and safety data for dabrafenib and trametinib combination therapy in Japanese patients with BRAF V600 mutation-positive advanced melanoma
    Takahashi, Akira
    Namikawa, Kenjiro
    Nakano, Eiji
    Yamazaki, Naoya
    JOURNAL OF DERMATOLOGY, 2020, 47 (03): : 257 - 264
12345